Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus

References

• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates on diabetes. Available from http://www.cdc.gov/diabetes/pubs/estimates.htm. [Accessed 14 April 2003]
   Google Scholar
• Pfeifer MA, Halter JB, Porte D, Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579–88
   PubMed Web of Science ®Google Scholar
• Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000;\(Suppl 113):3–13
   PubMedGoogle Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–72
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 2003;26(Suppl 1):S1–156
   PubMedGoogle Scholar
• American College of Endocrinology, American Association of Clinical Endocrinologists. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(Suppl 1):5–11
   PubMedGoogle Scholar
• Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321: 405–12
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161: 397–405
   PubMed Web of Science ®Google Scholar
• Rohlfing CL, Wiedmeyer H-M, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25: 275–8
   PubMed Web of Science ®Google Scholar
• Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20: 1822–6
   PubMed Web of Science ®Google Scholar
• Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 1999;46:23–7
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, et al., for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513–19
   PubMed Web of Science ®Google Scholar
• Bastyr EJ, III, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, et al., for the IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23: 1236–41
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists and American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management – 2002 update. Endocr Pract 2002;8(Suppl 1):41–82
   Google Scholar
• Goldberg RB, Holvey SM, Schneider J, for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849–56
   PubMed Web of Science ®Google Scholar
• Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT, the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997;20:597–606
   PubMed Web of Science ®Google Scholar
• Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, Bush A, et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 2000;319:143–8
   PubMed Web of Science ®Google Scholar
• Schmitz O, Lund S, Andersen PH, Jønler M, Pørksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care 2002;25: 342–6
   PubMed Web of Science ®Google Scholar
• Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001;24: 1221–5
   PubMed Web of Science ®Google Scholar
• Prescribing information: Glyset® (miglitol tablets). Physicians’ Desk Reference, 56th edn. Montvale, NJ: Medical Economics Company, 2002:2821–3
   Google Scholar
• Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001;52:193–204
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607–11
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Insulin secretagogues: sulfonylureas and repaglinide. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders, 3rd edn. Alexandria, VA: American Diabetes Association, 1998:160–70
   Google Scholar
• Prescribing Information: Glucophage®. Physicians’ Desk Reference, 52nd edn. Montvale, NJ: Medical Economics Company, 1998:795–800
   Google Scholar
• Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2002;15:398–402
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001;30:909–33
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Ohhira M, Miyokawa N, Kitamori S, Kohgo Y. Acarbose-induced hepatic injury [letter]. Lancet 1998;351:340
   PubMed Web of Science ®Google Scholar
• Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25: 330–6
   Google Scholar
• Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: application, benefits, and risks. Diabetes Rev 1995;3:308–34
   Google Scholar
• Mathur S, Barradas MA, Mikhailidis DP, Dandona P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diabetes Res 1990;14:133–8
   PubMedGoogle Scholar